Linked Life Data

1962115

Source:http://linkedlifedata.com/resource/pubmed/id/1962115

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
5
pubmed:dateCreated
1992-1-7
pubmed:abstractText
The study of the use of standard intravenous immunoglobulin (IVIG) preparations as adjunctive therapy for seriously ill patients is motivated by the need to restore immunoglobulin G depleted because of trauma or surgery and/or by the need to provide patients with specific antibodies to various microorganisms. Whereas no clinical studies have shown that standard IVIG has therapeutic efficacy, some data suggest that its prophylactic use is beneficial. Antisera or IVIG prepared from individuals who are hyperimmunized with the biologically active, highly conserved core portion of the endotoxin of gram-negative bacteria confer variable degrees of protection in animal models and clinical trials. Two clinical trials with use of monoclonal antibodies to core lipopolysaccharide have been completed. Only subsets of patients with gram-negative sepsis were protected by the monoclonal antibodies, but the results of the studies were discrepant in regard to the specific characteristics of patients who benefited from the administration of these antibodies. Further studies will be necessary to establish whether this therapy can be recommended for critically ill patients.
pubmed:commentsCorrections
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:issn
0162-0886
pubmed:author
pubmed:issnType
Print
pubmed:volume
13
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
985-92
pubmed:dateRevised
2005-11-16
pubmed:meshHeading
pubmed:articleTitle
Use of immunoglobulins in prevention and treatment of infection in critically ill patients: review and critique.
pubmed:affiliation
Division of Infectious Diseases, Centre Hospitalier, Universitaire Vaudois, Lausanne, Switzerland.
pubmed:publicationType
Journal Article, Review